Retatrutide Meets Endpoints in Pivotal TRIUMPH-1 Trial

Eli Lilly reported topline results on 21 May 2026 from TRIUMPH-1, its largest and longest Phase 3 study to date of the investigational triple-agonist retatrutide. The trial evaluated retatrutide, an investigational GIP, GLP-1, and glucagon triple hormone receptor agonist, in adults with obesity or overweight and at least one weight-related comorbidity without diabetes.

Retatrutide is a single molecule that acts on three receptors at once, which is why the sector has labelled it a triple-G candidate. That distinguishes it mechanistically from the dual-acting compounds already studied in the field.

Efficacy at 80 Weeks

The reported figures relate to body-weight change over 80 weeks. Among participants who stayed on treatment, the 12mg dose produced an average weight loss of 28%, the 9mg group 26%, and the 4mg group 19%, while the placebo arm saw an average loss of 2%. When the analysis included those who discontinued or switched to another weight-management drug, average losses were 18%, 24% and 25% across the doses, against 4% for placebo.

Trial Design

Trial design was straightforward. Lilly enrolled 2,339 participants and randomised equal numbers to a weekly 4, 9 or 12mg dose or placebo, with investigators following them for 80 weeks; around 500 continued into an extension that ended at 104 weeks.

Safety and Tolerability

On tolerability, the reported safety signals were consistent with the broader incretin class. Nausea, vomiting and other digestive problems were the main side effects, with the 12mg group showing an 11% discontinuation rate and the 4mg group a 4% rate, slightly lower than placebo.

What Comes Next

Retatrutide remains an investigational compound. Lilly has described it as investigational and first-in-class, and further TRIUMPH program results, including TRIUMPH-2 in type 2 diabetes and TRIUMPH-3 in established cardiovascular disease, are expected later this year. Lilly has said it will present full trial data at the American Diabetes Association scientific sessions.

For researchers tracking the triple-agonist class, the value here is the dataset: dose-ranging efficacy and tolerability over a long follow-up in a large, non-diabetic comorbidity population.

For educational purposes only. This content is informational and reflects publicly reported research developments. It is not medical advice and makes no therapeutic claims. Products referenced are for research use only. Consult a qualified healthcare professional for any medical question.